Skip to main content
PMC home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1982 Jan-Feb;55(1):27–47.

From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.

A Corbin
PMCID: PMC2595998  PMID: 6810559

Abstract

LHRH and its analogues produce profound antireproductive effects in both sexes of a variety of animal species. Although the LHRH agonists induce gonadotropin release, gonadal steroid secretion, ovulation, and spermatogenesis as an expression of their traditional profertility pharmacologic profile, they paradoxically and characteristically cause predominant antifertility effects which have been extensively evaluated for potential contraceptive purposes. These agonists produce their antireproductive effects in both males and females by common mechanisms, ultimately resulting in disruption of pituitary-gonadal function, depression of steroidogenesis, and inhibition of target organs dependent on such gonadal support. Similar antireproductive effects have been observed with the LHRH antagonists which competitively inhibit LHRH-induced gonadotropin secretion resulting in reduced blood gonadal steroid levels. Use of the inhibitory properties has been extended to cancer therapy based on the ability of the LHRH analogues (particularly the agonists) to inhibit the growth of steroid-dependent (responsive) tumors (e.g., mammary, prostate) similar to that produced by gonadectomy and antisteroid treatments. The use of these peptides for selected hormone-sensitive tumors presents a novel pharmacotherapeutic application for this class of drug.

Full text

PDF
27

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra J. C., Lippman M. E., Green L., Barlock A., Simon R., Thompson E. B., Huff K. K., Griffin W. Estrogen receptor values in patients with benign breast disease. Cancer. 1979 Jul;44(1):228–231. doi: 10.1002/1097-0142(197907)44:1<228::aid-cncr2820440137>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  2. Arafah B. M., Manni A., Pearson O. H. Effect of hypophysectomy and hormone replacement of hormone receptor levels and the growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Endocrinology. 1980 Nov;107(5):1364–1369. doi: 10.1210/endo-107-5-1364. [DOI] [PubMed] [Google Scholar]
  3. Auclair C., Givner M. L. Medrogestone and an LHRH analogue as potential combination therapy for hormone-dependent cancers. Arch Androl. 1982 Feb;8(1):21–24. doi: 10.3109/01485018208987013. [DOI] [PubMed] [Google Scholar]
  4. Auclair C., Stern M., Givner M. L. LHRH and analogues as potential therapy for benign prostatic hyperplasia and hormone-dependent cancers. Arch Androl. 1981 Nov;7(3):237–244. doi: 10.3109/01485018108999312. [DOI] [PubMed] [Google Scholar]
  5. Barber H. R. The effect of cancer and its therapy upon fertility. Int J Fertil. 1981;26(4):250–259. [PubMed] [Google Scholar]
  6. Belanger A., Auclair C., Ferland L., Caron S., Labrie F. Time-course of the effect of treatment with a potent LHRH agonist on testicular steroidogenesis and gonadotropin receptor levels in the adult rat. J Steroid Biochem. 1980 Feb;13(2):191–196. doi: 10.1016/0022-4731(80)90191-0. [DOI] [PubMed] [Google Scholar]
  7. Bex F. J., Corbin A., France E. Resistance of the mouse to the antifertility effects of LHRH agonists. Life Sci. 1982 Apr 12;30(15):1263–1269. doi: 10.1016/0024-3205(82)90688-9. [DOI] [PubMed] [Google Scholar]
  8. Bulbrook R. D., Wang D. Y., Hayward J. L., Kwa H. G., Cleton F. Plasma prolactin levels and age in a female population: relation to breast cancer. Int J Cancer. 1981 Jul 15;28(1):43–45. doi: 10.1002/ijc.2910280108. [DOI] [PubMed] [Google Scholar]
  9. Campbell F. C., Blamey R. W., Elston C. W., Morris A. H., Nicholson R. I., Griffiths K., Haybittle J. L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981 Dec 12;2(8259):1317–1319. doi: 10.1016/s0140-6736(81)91341-6. [DOI] [PubMed] [Google Scholar]
  10. Danguy A., Legros N., Heuson-Stiennon J. A., Pasteels J. L., Atassi G., Heuson J. C. Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies. Eur J Cancer. 1977 Oct;13(10):1089–1094. doi: 10.1016/0014-2964(77)90005-6. [DOI] [PubMed] [Google Scholar]
  11. DeSombre E. R., Johnson E. S., White W. F. Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res. 1976 Oct;36(10):3830–3833. [PubMed] [Google Scholar]
  12. Dickson R. B., Clark C. R. Estrogen receptors in the male. Arch Androl. 1981 Nov;7(3):205–217. doi: 10.3109/01485018108999309. [DOI] [PubMed] [Google Scholar]
  13. Faure N., Labrie F., Lemay A., Bélanger A., Gourdeau Y., Laroche B., Robert G. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertil Steril. 1982 Mar;37(3):416–424. doi: 10.1016/s0015-0282(16)46107-8. [DOI] [PubMed] [Google Scholar]
  14. Furr B. J., Nicholson R. I. Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer. J Reprod Fertil. 1982 Mar;64(2):529–539. doi: 10.1530/jrf.0.0640529. [DOI] [PubMed] [Google Scholar]
  15. Glode L. M., Robinson J., Gould S. F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981 May 23;1(8230):1132–1134. doi: 10.1016/s0140-6736(81)92301-1. [DOI] [PubMed] [Google Scholar]
  16. Gore-Langton R. E., Lacroix M., Dorrington J. H. Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. Endocrinology. 1981 Mar;108(3):812–819. doi: 10.1210/endo-108-3-812. [DOI] [PubMed] [Google Scholar]
  17. Hoffman P. G., Siiteri P. K. Sex steroid receptors in gynecologic cancer. Obstet Gynecol. 1980 May;55(5):648–652. [PubMed] [Google Scholar]
  18. Howanitz J. H. Hormone receptors and breast cancer. Hum Pathol. 1981 Dec;12(12):1057–1059. doi: 10.1016/s0046-8177(81)80327-9. [DOI] [PubMed] [Google Scholar]
  19. Hsueh A. J., Jones P. B. Extrapituitary actions of gonadotropin-releasing hormone. Endocr Rev. 1981 Fall;2(4):437–461. doi: 10.1210/edrv-2-4-437. [DOI] [PubMed] [Google Scholar]
  20. Hähnel R., Martin J. D., Masters A. M., Ratajczak T., Twaddle E. Estrogen receptors and blood hormone levels in cervical carcinoma and other gynecological tumors. Gynecol Oncol. 1979 Oct;8(2):226–233. doi: 10.1016/0090-8258(79)90029-5. [DOI] [PubMed] [Google Scholar]
  21. Johnson E. S., Seely J. H., White W. F., DeSombre E. R. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. Science. 1976 Oct 15;194(4262):329–330. doi: 10.1126/science.823643. [DOI] [PubMed] [Google Scholar]
  22. Jordan V. C., Dix C. J., Naylor K. E., Prestwich G., Rowsby L. Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health. 1978 Mar-May;4(2-3):363–390. doi: 10.1080/15287397809529666. [DOI] [PubMed] [Google Scholar]
  23. Kauppila A., Friberg L. G. Hormonal and cytotoxic chemotherapy for endometrial carcinoma. Steroid receptors in the selection of appropriate therapy. Acta Obstet Gynecol Scand Suppl. 1981;101:59–64. doi: 10.3109/00016348109157814. [DOI] [PubMed] [Google Scholar]
  24. Kwa H. G., Cleton F., Wang D. Y., Bulbrook R. D., Bulstrode J. C., Hayward J. L., Millis R. R., Cuzick J. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int J Cancer. 1981 Dec;28(6):673–676. doi: 10.1002/ijc.2910280603. [DOI] [PubMed] [Google Scholar]
  25. Labrie F., Cusan L., Séguin C., Bélanger A., Pelletier G., Reeves J., Kelly P. A., Lemay A., Raynaud J. P. Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int J Fertil. 1980;25(3):157–170. [PubMed] [Google Scholar]
  26. Lamberts S. W., Uitterlinden P., Zuiderwijk-Roest J. M., Bons-van Evelingen E. G., de Jong F. H. Effects of a luteinizing hormone-releasing hormone analog and tamoxifen on the growth of an estrogen-induced prolactin-secreting rat pituitary tumor and its influence on pituitary gonadotropins. Endocrinology. 1981 May;108(5):1878–1884. doi: 10.1210/endo-108-5-1878. [DOI] [PubMed] [Google Scholar]
  27. Lin Y. C., Loring J. M., Villee C. A. Permissive role of the pituitary in the induction and growth of estrogen-dependent renal tumors. Cancer Res. 1982 Mar;42(3):1015–1019. [PubMed] [Google Scholar]
  28. Linde R., Doelle G. C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981 Sep 17;305(12):663–667. doi: 10.1056/NEJM198109173051203. [DOI] [PubMed] [Google Scholar]
  29. Loven D., Rakowsky E., Stein J. A., Geier A., Lunenfeld B. Hormonal receptors and response to treatment of breast cancer: a retrospective evaluation in 60 patients. Isr J Med Sci. 1981 Sep-Oct;17(9-10):960–964. [PubMed] [Google Scholar]
  30. Marx J. L. Tumors; a mixed bag of cells. Science. 1982 Jan 15;215(4530):275–277. doi: 10.1126/science.7053575. [DOI] [PubMed] [Google Scholar]
  31. Maynard P. V., Nicholson R. I. Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats. Br J Cancer. 1979 Mar;39(3):274–279. doi: 10.1038/bjc.1979.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mehta A. E., Tolis G., Goodyer C., McInnes R. Prolactin update. Pathobiol Annu. 1981;11:337–389. [PubMed] [Google Scholar]
  33. Metz S. A., Weintraub B., Rosen S. W., Singer J., Robertson R. P. Ectopic secretion of chorionic gonadotropin by a lung carcinoma. Pituitary gonadotropin and subunit secretion and prolonged chemotherapeutic remission. Am J Med. 1978 Aug;65(2):325–333. doi: 10.1016/0002-9343(78)90827-6. [DOI] [PubMed] [Google Scholar]
  34. Neumann F. Pharmacology and potential use of cyproterone acetate. Horm Metab Res. 1977 Jan;9(1):1–13. doi: 10.1055/s-0028-1093574. [DOI] [PubMed] [Google Scholar]
  35. Nicholson R. I., Finney E. J., Maynard P. V. Activity of a new analogue of luteinizing hormone releasing hormone, ICI 118630, on the growth of rat mammary tumours [proceedings]. J Endocrinol. 1978 Nov;79(2):51P–52P. [PubMed] [Google Scholar]
  36. Nicholson R. I., Maynard P. V. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer. 1979 Mar;39(3):268–273. doi: 10.1038/bjc.1979.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Pearson J., Friedman M. A., Hoffman P. G., Jr Hormone receptors in renal cell carcinoma. Their utility as predictors of response to endocrine therapy. Cancer Chemother Pharmacol. 1981;6(2):151–154. doi: 10.1007/BF00262335. [DOI] [PubMed] [Google Scholar]
  38. Redding T. W., Coy D. H., Schally A. V. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1273–1276. doi: 10.1073/pnas.79.4.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Redding T. W., Schally A. V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ricciardi I., Ianniruberto A. Tamoxifen-induced regression of benign breast lesions. Obstet Gynecol. 1979 Jul;54(1):80–84. doi: 10.1097/00006250-197907000-00018. [DOI] [PubMed] [Google Scholar]
  41. Rivier C., Vale W. Hormonal secretion in male rats chronically treated with [D-Trp6, Pro9-NEt]-LRF. Life Sci. 1979 Sep 17;25(12):1065–1074. doi: 10.1016/0024-3205(79)90592-7. [DOI] [PubMed] [Google Scholar]
  42. Rose D. P., Noonan J. J. Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea. Cancer Res. 1982 Jan;42(1):35–38. [PubMed] [Google Scholar]
  43. Rose D. P., Pruitt B. T. Plasma prolactin levels in patients with breast cancer. Cancer. 1981 Dec 15;48(12):2687–2691. doi: 10.1002/1097-0142(19811215)48:12<2687::aid-cncr2820481221>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  44. Rose D. P., Pruitt B. Modification of the effect of a gonadoliberin analog on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by hormone replacement. Cancer Res. 1979 Oct;39(10):3968–3970. [PubMed] [Google Scholar]
  45. STERENTAL A., DOMINGUEZ J. M., WEISSMAN C., PEARSON O. H. Pituitary role in the estrogen dependency of experimental mammary cancer. Cancer Res. 1963 Mar;23:481–484. [PubMed] [Google Scholar]
  46. Saez S. Récepteurs des stéroïdes sexuels dans les tumeurs malignes. Ann Endocrinol (Paris) 1981 Oct-Nov;42(4-5):306–314. [PubMed] [Google Scholar]
  47. Sarg M. J., Jr Chemotherapy for breast cancer. J Reprod Med. 1979 Jul;23(1):3–11. [PubMed] [Google Scholar]
  48. Sundaram K., Cao Y. Q., Wang N. G., Bardin C. W., Rivier J., Vale W. Inhibition of the action of sex steroids by gonadotropin-releasing hormone (GnRH) agonists: a new biological effect. Life Sci. 1981 Jan 5;28(1):83–88. doi: 10.1016/0024-3205(81)90369-6. [DOI] [PubMed] [Google Scholar]
  49. Séguin C., Cusan L., Bélanger A., Kelly P. A., Labrie F., Raynaud J. P. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol Cell Endocrinol. 1981 Jan;21(1):37–41. doi: 10.1016/0303-7207(81)90028-9. [DOI] [PubMed] [Google Scholar]
  50. Taylor R. E., Powles T. J., Humphreys J., Bettelheim R., Dowsett M., Casey A. J., Neville A. M., Coombes R. C. Effects of endocrine therapy on steroid-receptor content of breast cancer. Br J Cancer. 1982 Jan;45(1):80–85. doi: 10.1038/bjc.1982.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Teodorczyk-Injeyan J., Jewett M. A., Kellen J. A., Malkin A. Gonadoliberin (LHRH) mediated release of choriogonadotropin in experimental human and animal tumors in vitro. Endocr Res Commun. 1981;8(1):19–24. doi: 10.1080/07435808109065980. [DOI] [PubMed] [Google Scholar]
  52. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tolis G., Mehta A., Comaru-Schally A. M., Schally A. V. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest. 1981 Sep;68(3):819–822. doi: 10.1172/JCI110320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Trachtenberg J., Bujnovszky P., Walsh P. C. Androgen receptor content of normal and hyperplastic human prostate. J Clin Endocrinol Metab. 1982 Jan;54(1):17–21. doi: 10.1210/jcem-54-1-17. [DOI] [PubMed] [Google Scholar]
  55. Tsai T. L., Rutledge S., Katzenellenbogen B. S. Antiestrogen modulation of the growth and properties of ovarian-autonomous and ovarian-dependent mammary tumors in rats. Cancer Res. 1979 Dec;39(12):5043–5050. [PubMed] [Google Scholar]
  56. Turcot-Lemay L., Cusan L., Séquin C., Kelly P., Labrie F. Effect of an LHRH analog on growth and hormone receptor levels in DMBA-induced mammary tumors in the rat. J Recept Res. 1981;2(2):135–151. doi: 10.3109/10799898109039258. [DOI] [PubMed] [Google Scholar]
  57. Vihko R., Vierikko P. Determinations of steroid receptors and their clinical applications. Acta Obstet Gynecol Scand Suppl. 1981;101:21–28. doi: 10.3109/00016348109157807. [DOI] [PubMed] [Google Scholar]
  58. Young P. C., Keen F. K., Einhorn L. H., Stanich B. M., Ehrlich C. E., Cleary R. E. Binding of medroxyprogesterone acetate in human breast cancer. Am J Obstet Gynecol. 1980 Jun 1;137(3):284–292. doi: 10.1016/0002-9378(80)90911-4. [DOI] [PubMed] [Google Scholar]
  59. Zumoff B., Levin J., Kream J., Strain G. W., Markham M., Fukushima D. K. Subnormal 24-hour mean concentration and abnormal 24-hour profile of plasma LH in the luteal phase in women with breast cancer. Anticancer Res. 1981;1(5):305–308. [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES